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Summary 
 
 The RNA genome of nonsegmented negative-strand RNA virus is completely covered 
by the nucleoprotein (N) forming a ribonucleoprotein complex, the nucleocapsid. The 
nucleocapsid functions as the template for viral RNA synthesis that is mediated by a viral 
RNA-dependent RNA polymerase. We postulated that the selection of molecules that would 
specifically target the nucleocapsid and thus inhibit the viral polymerase activity could 
represent a common approach to block negative-strand RNA viruses. We present the 
characterization of two single-chain antibody fragments (scFv) that were selected using the 
phage display technology and that specifically interacted with vesicular stomatitis virus 
(VSV) nucleocapsid. The two recombinant antibodies recognize a conformational epitope on 
the nucleocapsid and specifically immunoprecipitate nucleocapsids from infected cell 
extracts. Both antibodies have a strong inhibitory effect on VSV transcription activity in vitro 
and thus represent promising molecules to inhibit viral RNA synthesis in vivo. 
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 Vesicular stomatitis virus (VSV), a pathogen for domestic cattle, is a member of the 
Rhabdoviridae family. The genetic organization of Rhabdoviridae is similar to 
Paramyxoviridae and Filoviridae that belong to the same order of Mononegavirales (Rose, 
2001). Viruses belonging to this order such as Newcastle diseases and rinderpest have a major 
economic impact on animal rearing, and many others are responsible of numerous diseases in 
humans that range from acute respiratory diseases (respiratory syncytial and parainfluenza 
viruses) to hemorrhagic fever (Ebola and Marburg viruses) and encephalitis (Hendra and 
Nipah viruses).  
In many aspects, transcription and replication of these single strand, negative-sense 
RNA viruses are similar (Whelan et al., 2004). In infected cells, RNA synthesis is restricted to 
the cytoplasm and is mediated by the viral RNA-dependent RNA polymerase that is only 
active on the genomic/antigenomic RNA tightly enwrapped by the nucleoprotein (N). This 
ribonucleoprotein complex, or nucleocapsid, serves as a template for both mRNA synthesis 
and replication. 
Although different vaccines have been developed against few Mononegavirales a 
general antiviral strategy to block these viruses is still lacking. Molecules that would 
specifically target the nucleocapsids and inhibit viral RNA synthesis would lead to the 
development of new antiviral drugs. 
Recently, a new class of neutralizing molecules called intracellular antibodies 
(intrabodies) has been described (Chen et al., 1994, Marasco, 1997). Single-chain antibody 
fragments (scFv) have been successfully used to inhibit the function of certain intracellular 
target proteins and were shown to have promising therapeutic applications (Lobato & 
Rabbitts, 2003, Rondon & Marasco, 1997, Stocks, 2004). ScFv consists of a single 
polypeptide chain that contains the variable regions of heavy (VH) and light (VL) chain 
separated by a short polypeptide linker (Clackson et al., 1991, McCafferty et al., 1990). These 
recombinant antibodies are produced from combinatorial libraries of immunoglobulin genes 
that are functionally expressed on the surface of filamentous phages (Griffiths et al., 1994). 
High affinity antibodies that are specific of a target protein are selected during several rounds 
of in vitro affinity selection. ScFv directed against the target protein can then be expressed 
inside cells and their inhibitory properties can be evaluated (Maciejewski et al., 1995, 
Marasco et al., 1993, Mhashilkar et al., 1995). 
As a proof of concept, we report the identification of two recombinant antibodies 
(scFv) that have been selected to specifically recognize VSV nucleocapsids. These antibodies 
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have a strong inhibitory effect on VSV transcription in vitro and may represent promising 
molecules to block viral RNA synthesis in vivo. 
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 To select for human anti-nucleocapsid antibodies by phage display, nucleocapsids of 
VSV Indiana strain were purified from BHK-21 (baby hamster kidney) infected cells. Twenty 
hours post-infection cells were collected and lysed into a 0.6 % NP-40 containing buffer. The 
lysate was loaded onto a 20-40% CsCl gradient (W/W) and centrifuged for 17 hours at 32000 
r.p.m. in a SW 41 rotor. The pure nucleocapsids that form a visible band in the gradient were 
recovered by puncture of the tube and dialysed against PBS. Previous reports have shown that 
the nucleocapsids purified in these conditions are transcriptionally active in in vitro assay 
(Moyer et al., 1991). One microgram of purified nucleocapsid, analysed by SDS-PAGE 
reveals a single band with the expected 45 kDa molecular mass of the nucleoprotein (Fig 1A, 
lane 1). The nucleocapsids were then biotinylated, in vitro, by the addition of NHS-LC-Biotin 
(PIERCE) in a 1:1 molar ratio. The reaction was performed at room temperature, for 1 hour, 
on a rotating wheel and stopped by adjusting the reaction to 100 mM glycine. Non-reacted 
biotin was removed by ultrafiltration through a 100 kDa MWCO Vivaspin concentrator 
device (Vivascience). No significant change in the migration of the nucleoprotein on SDS-
PAGE was observed upon biotinylation (Fig 1A, compare lanes 1 and 2). 
For the panning step, 100 µg of biotinylated nucleocapsids were incubated with 50 µl 
of streptavidin-coupled magnetic beads (Streptavidin M-280 Dynabeads, Dynal) in binding 
buffer (PBS + 0,1% Tween 20) for two hours, end over end, at 4°C. The beads were then 
recovered on a magnet. To estimate the yield of captured nucleocapsids, the streptavidin-
coated beads were analysed on SDS-PAGE. In these conditions, 5 to 10 µg of nucleocapsids 
were reproducibly bound to the magnetic beads (Fig 1A, lanes 3 and 4). 
 The human Tomlinson I+J library (obtained from the MRC Centre for Protein 
Engineering, Cambridge, UK) was used for affinity selection of anti-nucleocapsid antibodies. 
This library contains more than 200 million different scFvs, each one consisting of a single 
polypeptide composed of the VH and VL immunoglobulin variable regions separated by a 
flexible glycine/serine-rich linker. The rounds of selection were essentially performed 
according to the manufacturer’s instructions 
(http://www.hgmp.mrc.ac.uk/geneservice/reagents/products/datasheets/scFv/tomlinsonIJ.pdf). 
Briefly, biotinylated nucleocapsids bound to streptavidin-coated beads were incubated with 
1.5.1012 scFv displaying phages in binding buffer complemented with 2% fat-free milk 
(Marvel) for 1.5 hour at 4°C. After twenty washes in binding buffer, the nucleocapsid-bound 
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phages were eluted with 100 mM triethylamine (pH11) and amplified in the Escherichia coli 
TG1 strain to achieve the next round of selection. As shown in figure 1B, the phage recovery 
yield increased about 10
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3 folds over the three rounds, indicating a positive selection. Thus, we 
stopped the selection after the third round and randomly picked 25 clones of the phagemid-
containing TG1 cells. The supernatant of each clone (secreting a single scFv) was tested by 
ELISA for its ability to bind to purified nucleocapsids (data not shown). Seven scFvs reacted 
positively in that assay. DNA sequencing of each positive clones revealed that six of them 
were identical showing the effectiveness of the selection. The protein sequence of two 
different positive clones (named Nuc 3 and Nuc 25) is shown in figure 1C. The sequence of 
Nuc 1, which was initially selected but was not reactive in ELISA, is also presented. 
 For functional characterization, the soluble (His)6-tagged scFvs were produced in the 
E. coli HB 2151 strain and purified from the periplasmic space by immobilized metal affinity 
chromatography (IMAC) using a Ni-Sepharose High Performance resin (Pharmacia Biotech) 
as described by the manufacturer. The eluted scFvs migrated as a single band on Coomassie 
blue stained SDS-PAGE (data not shown). A one-liter bacterial culture yielded from 2 to 10 
mg of scFv that were kept at -20°C in 50% glycerol. 
 The purified Nuc 3 and Nuc 25 antibodies failed to recognize VSV nucleoprotein in 
Western blotting experiments (data not shown). However, the two scFvs were reactive in dot 
blot assay when cytoplasmic extracts from VSV-infected cells were blotted onto a 
nitrocellulose membrane (Fig 2A). Both antibodies are highly specific of a viral antigen since 
no background reactivity could be detected in non-infected cytoplasmic extract. Furthermore, 
Nuc 1 did not react with VSV infected cell extract. The observation that these antibodies were 
reactive against native antigens (in dot blot assay) and failed to bind to denatured ones (in 
Western blot assay) indicated that they did recognize a conformational epitope. This 
observation led us to ask whether these antibodies could be efficiently used in 
immunoprecipitation experiments. 
 To determine the ability of Nuc 3 and Nuc 25 to immunoprecipitate nucleocapsids 
from VSV-infected extract, the (His)6-tagged scFvs were immobilized on Ni-NTA magnetic 
agarose beads (Qiagen) and incubated with protein extracts. After three washes in stringent 
saline conditions (PBS buffer supplemented with 0.5 M NaCl), proteins bound to the 
antibodies were separated by SDS-PAGE and immunoblotted with an anti-VSV polyclonal 
antibody. In theses conditions Nuc 3 and Nuc 25, but not Nuc 1, could efficiently 
immunoprecipitate the nucleocapsids produced in VSV-infected cells (Fig 2B). The 
specificity of the interaction between the antibodies and the nucleocapsid was analysed by 
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Coomassie blue staining of the same immunoprecipitated samples. The gel in figure 2C shows 
that even though the 2 scFvs were mixed with a large amounts of infected extracts (1,7 mg), 
only the nucleocapsids were immunoprecipitated and no contaminant protein could be 
detected. This data confirms the high specificity of the selected antibodies towards VSV 
nucleocapsids. 
 The recombinant antibodies were then used for immunostaining of VSV-infected cells. 
Vero cells were fixed 8 hours post-infection in 4 % paraformaldehyde, and permeabilised 
with 0.3% Triton X-100. As shown in Fig 2D, both Nuc 3 and Nuc 25 labelled prominent 
cytoplasmic inclusion bodies that are characteristic of nucleocapsids (Arnheiter et al., 1985). 
These structures were neither observed in the non-infected cells shown in the same field nor 
in cells labelled with the control antibody Nuc 1. 
 All together, our data clearly demonstrated that the two recombinant antibodies 
selected by the phage display approach recognized VSV nucleocapsids with high specificity. 
This observation prompted us to evaluate the potential inhibitory properties of Nuc 3 and Nuc 
25 on VSV RNA synthesis. For this purpose in vitro transcription of detergent-disrupted VSV 
was performed in the presence of Nuc 3 and Nuc 25. In this assay, 5 µg of glycerol gradient-
purified VSV (disrupted into a mix containing 0.2 % Triton X-100, 100 mM Tris-HCl (pH 8), 
70 mM NaCl, 5 mM MgCl2, 1 mM DTT, 5 mM spermidine) were incubated for 15 min at 4 
°C with the different scFvs at various concentrations as indicated in figure 3. The in vitro 
transcription reaction was then initiated by addition of a mix containing 1 mM ATP, 1 mM 
CTP, 1 mM GTP, 0.2 mM UTP, 20 µCi 32P-UTP (3000Ci/mmol) and 80 units of RNasin 
(Promega). After 60 min at 30°C, transcripts were precipitated in 25% trichloroacetic acid. As 
shown in figure 3, Nuc 3 and Nuc 25 displayed a dose-dependent inhibitory effect on VSV 
transcription activity with 20%, 55% and > 95% inhibition when added at a concentration of 5 
µg/ml, 10 µg/ml and 100 µg/ml, respectively. Only minor inhibitory effects, not exceeding 
20% at the highest concentration, could be detected with the control antibody Nuc 1. Thus, 
Nuc 3 and Nuc 25 recombinant antibodies represent good candidates to inhibit VSV RNA 
synthesis in vivo. 
 
 In this study we report the use of the scFv phage display technology to identify new 
proteins with potential antiviral activities against negative strand RNA viruses. We reasoned 
that the selection of molecules targeting the nucleocapsid and thus preventing RNA synthesis 
could represent a common strategy to block spread of these viruses. Ideally, the selected 
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recombinant antibodies would interact with high affinity and specificity with the nucleocapsid 
and would prevent the motion of the viral RNA polymerase on this complex. 
For this purpose, the phage display technology bears a certain number of advantages. 
The most interesting one is the possibility to perform the affinity selection with biologically 
functional antigens, which allows the selection for scFv recognizing conformational epitopes. 
Recombinant antibodies that target proteins in native state are more likely to act as 
neutralizing molecules in vivo as those recognizing denatured proteins. In our experiments the 
in vitro affinity selection was done with transcription-competent nucleocapsids and the two 
conformational antibodies that derived from this selection were found to efficiently block 
VSV transcription. 
 The challenge for the future will be to express these recombinant antibodies 
intracellularly and show that they can efficiently block VSV RNA synthesis. To be used as 
potential therapeutic agents, scFvs must be stably expressed inside the cell. Unfortunately, the 
strong reducing environment of the cytoplasm tends to prevent the formation of disulphide 
bonds that are necessary for the proper folding of scFv (Schouten et al., 2002). To circumvent 
this problem and in order to build successful intrabodies, several strategies can be proposed. 
One of them is to perform strategic point mutations in the VH and VL domains of the selected 
antibody (Ohage & Steipe, 1999, Wirtz & Steipe, 1999). The fusion of a module (such as the 
C region of κ light chain (C κ) or the constant region fragment (Fc) of IgG) has also been 
used with success to stabilize scFv (Strube & Chen, 2004). We are currently trying to 
manipulate the scFvs presented in this study in order to obtain stable intrabodies able to 
inhibit VSV RNA synthesis in vivo. 
 The recombinant antibodies describe here can easily be produced in large amounts and 
in soluble form in bacteria. Therefore, they will be used for immunoprecipitation analysis of 
viral complexes and to investigate the interaction between the nucleocapsids and their 
potential cellular partners. 
 On the other hand, Nuc 3 and Nuc 25 antibodies will also be used for structural 
analysis. Mapping of their binding site and resolution of the tri-dimensional structure of VSV 
N protein in complex with the antibodies may provide us with some clue for the design by 
structural modelling of smaller inhibitors which would be better suited for intracellular 
delivery. 
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Figure 1: Selection of scFv that specifically interact with VSV nucleocapsid. 
A) SDS-PAGE analysis of VSV nucleocapsids. Lane 1, 1 µg of gradient-purified 
nucleocapsid. Lane 2, 0,5 µg of biotinylated nucleocapsid. Lanes 3 and 4, nucleocapsids 
captured on strepatvidin coated beads. One half of the recovered beads are loaded in each 
lane. Proteins were stained with Coomassie blue. N: nucleoprotein, *: monomers of 
streptavidin (13 kDa) released from the beads during SDS-PAGE. B) Ratio, for each cycle of 
selection, between the number of nucleocapsid-bound phages (output) and the number of scFv 
displaying phages used for the selection (input). C) Protein sequence alignment of the 3 scFvs 
used in this study. VH and VL immunoglobulin variable regions lie between AA 1-116 and 
134-241, respectively. Asterisks indicate amino-acid differences between the sequences. The 
glycine/serine linker, the (His)6-tag and the myc epitope are also indicated. 
 
Figure 2: Functional characterization of the selected scFv. 
A) VSV-infected and non infected cytoplasmic extracts were blotted onto a nitrocellulose 
membrane. Recombinant antibodies from 50% glycerol stocks were used at 1/200 dilution 
and mixed with an anti-myc monoclonal antibody (9E10). ScFv binding was revealed by 
peroxidase activity detection with a light-based ECL system (PIERCE). B) VSV 
nucleocapsids were immunoprecipitated from cytoplasmic extract obtained from VSV-
infected cells with Nuc 1, Nuc 3 and Nuc 25. The samples were loaded on a 12 % SDS-
PAGE, transferred and immunobloted with an anti-VSV polyclonal antibody used at a 1/2000 
dilution. Lane Ctl: gradient-purified nucleocapsid. C) The immunoprecipitated samples 
described in Fig 2B were loaded on a 12 % SDS-PAGE and stained with Coomassie blue. D) 
Vero cells were infected with VSV (at m.o.i. 1) for 8 hours at 37°C. Cells were incubated 
with Nuc 1, Nuc 3 or Nuc 25 (at 1/100 dilution), mixed with anti-myc (9E10) and anti-His 
(clone HIS-1, Sigma) mAbs. Nucleocapsids were stained with a FITC-labelled anti-mouse Ig 
conjugate (green) whereas nuclei were stained with Hoechst (blue). Pictures were taken with a 
Zeiss Axioplan 2 fluorescence microscope and processed with AnalySiS 3.0 software. 
 
Figure 3: Inhibition of VSV RNA synthesis in vitro by recombinant scFv. 
RNA synthesis was performed from detergent-disrupted VSV in presence of indicated 
amounts of each scFv. Incorporation of 32P-UTP into transcribed RNA was determined by 
liquid scintillation counting after TCA precipitation. Transcription activity was expressed as 
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the percentage of a control reaction without scFv. Each reaction was performed in triplicate. 
Error bars represent the standard deviation of the data. 
 
Acknowledgements 
 
The authors would like to thank Dr D. Blondel (laboratoire de Virologie Moléculaire et 
Structurale, UMR 2472) for providing us with the VSV polyclonal antibody. We would like 
to thank Dr F. Perez (Institut Curie, UMR 144) for the help with the affinity selection and Dr 
L. Merendino for critical reading of the manuscript. F.I was supported by a grant from the 
Région Rhône-Alpes (contrat Emergence). 
 
References 
 
Arnheiter, H., Davis, N. L., Wertz, G., Schubert, M. & Lazzarini, R. A. (1985). Role of the 
nucleocapsid protein in regulating vesicular stomatitis virus RNA synthesis. Cell 41, 
259-67. 
Chen, S. Y., Bagley, J. & Marasco, W. A. (1994). Intracellular antibodies as a new class of 
therapeutic molecules for gene therapy. Hum Gene Ther 5, 595-601. 
Clackson, T., Hoogenboom, H. R., Griffiths, A. D. & Winter, G. (1991). Making antibody 
fragments using phage display libraries. Nature 352, 624-8. 
Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., Crosby, W. 
L., Kontermann, R. E., Jones, P. T., Low, N. M., Allison, T. J. & et al. (1994). 
Isolation of high affinity human antibodies directly from large synthetic repertoires. 
Embo J 13, 3245-60. 
Lobato, M. N. & Rabbitts, T. H. (2003). Intracellular antibodies and challenges facing their 
use as therapeutic agents. Trends Mol Med 9, 390-6. 
Maciejewski, J. P., Weichold, F. F., Young, N. S., Cara, A., Zella, D., Reitz, M. S., Jr. & 
Gallo, R. C. (1995). Intracellular expression of antibody fragments directed against 
HIV reverse transcriptase prevents HIV infection in vitro. Nat Med 1, 667-73. 
Marasco, W. A. (1997). Intrabodies: turning the humoral immune system outside in for 
intracellular immunization. Gene Ther 4, 11-5. 
Marasco, W. A., Haseltine, W. A. & Chen, S. Y. (1993). Design, intracellular expression, and 
activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain 
antibody. Proc Natl Acad Sci U S A 90, 7889-93. 
 8
273 
274 
275 
276 
277 
278 
279 
280 
281 
282 
283 
284 
285 
286 
287 
288 
289 
290 
291 
292 
293 
294 
295 
296 
297 
298 
299 
McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. (1990). Phage antibodies: 
filamentous phage displaying antibody variable domains. Nature 348, 552-4. 
Mhashilkar, A. M., Bagley, J., Chen, S. Y., Szilvay, A. M., Helland, D. G. & Marasco, W. A. 
(1995). Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by 
anti-Tat single chain intrabodies. Embo J 14, 1542-51. 
Moyer, S. A., Smallwood-Kentro, S., Haddad, A. & Prevec, L. (1991). Assembly and 
transcription of synthetic vesicular stomatitis virus nucleocapsids. J Virol 65, 2170-8. 
Ohage, E. & Steipe, B. (1999). Intrabody construction and expression. I. The critical role of 
VL domain stability. J Mol Biol 291, 1119-28. 
Rondon, I. J. & Marasco, W. A. (1997). Intracellular antibodies (intrabodies) for gene therapy 
of infectious diseases. Annu Rev Microbiol 51, 257-83. 
Rose, J. K., Whitt, M.A. (2001). Rhabdoviridae: The viruses and their replication. In Fields 
Virology, 4th edn, pp. 1221-1244. Edited by D. M. Knipe, Howley, P.M. Philadelphia: 
Lippincott, Williams & Wilkins. 
Schouten, A., Roosien, J., Bakker, J. & Schots, A. (2002). Formation of disulfide bridges by a 
single-chain Fv antibody in the reducing ectopic environment of the plant cytosol. J 
Biol Chem 277, 19339-45. 
Stocks, M. R. (2004). Intrabodies: production and promise. Drug Discov Today 9, 960-6. 
Strube, R. W. & Chen, S. Y. (2004). Enhanced intracellular stability of sFv-Fc fusion 
intrabodies. Methods 34, 179-83. 
Whelan, S. P., Barr, J. N. & Wertz, G. W. (2004). Transcription and replication of 
nonsegmented negative-strand RNA viruses. Curr Top Microbiol Immunol 283, 61-
119. 
Wirtz, P. & Steipe, B. (1999). Intrabody construction and expression III: engineering 
hyperstable V(H) domains. Protein Sci 8, 2245-50. 
 
 
 9
AB
O
u
t
p
u
t
/
I
n
p
u
t
10-03
10-04
10-05
10-06
10-07
10-08
10-09
10-10
1 2 3
Round of selection Cortay et al. Fig 1
32 41
*
kDa
83
62
47
32
25
16
6
N
C
A
+ ++- - -VSV:
Nuc 3Nuc 1 Nuc 25
N
kDa
175
83
47
62
32
25
16
Ctl 1 3 25
Nuc
scFv
C
D Nuc 1 Nuc 25Nuc 3
B
A
nt
i-V
SV
N
Ctl 1 3 25
Nuc
Cortay et al. Fig 2
Tr
a
n
s
c
r
i
p
t
i
o
n
 
a
c
t
i
v
i
t
y
(
%
)
0
10
20
30
40
50
60
70
80
90
100
10 1005
Nuc 1
Nuc 3
Nuc 25
scFv (µg/ml)
Cortay et al. Fig 3
